HOHans Orlent

Hans Orlent

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans Orlent has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ethnicity, genomic ancestry, and HBV genotype in off-treatment outcomes following nucleos(t)ide analogue cessation: a prospective multicentre trial (COIN-B)

    by Arno Furquim D’ALmeida, Axelle Vanderlinden, Arwin Ralf, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Sersté, Mathieu Struyve, Baro Deressa, Dirk Sprengers, Marie de Vos, et al.

    Nucleos(t)ide analogue (NUC) cessation can induce functional cure, but outcomes vary. Ethnicity has been suggested as a determinant, but definitions are subjective and inconsistent. In this prospective, multicentre trial (NCT04779970, EudraCT 2021-001003-32), 91 long-term NUC-treated, start-of-treatment HBeAg-negative patients without advanced fibrosis discontinued treatment; 84 completed the 72-week protocol. In the prespecified analysis, off-treatment viral control at week 72 (primary endpoint) did not differ between Caucasians (n = 41) and non-Caucasians (n = 43) (41.5% vs 30.2%, p = 0.28). In exploratory analyses, HBsAg loss (7.1%, secondary endpoint) occurred exclusively in European or North African/Middle Eastern genomic ancestries, and ≥1 log IU/mL HBsAg decline was less frequent in Asian or Sub-Saharan African ancestries (p = 0.01). Lower end-of-treatment HBsAg independently predicted viral control, HBsAg loss and decline. Adjusted for end-of-treatment HBsAg, genotypes C and D achieved less viral control and required more retreatment than genotype A. Here, we show that genomic ancestry and HBV genotype capture clinically relevant heterogeneity, calling for more granular characterization of eligible populations. Clinical trial information EudraCT: 2021-001003-32. Date of registration: 7 June 2021 CTIS: 2024-511016-25-00. Date of transition from EudraCT: 15 January 2025 Clinicaltrials.gov: NCT04779970. Date of registration: 28 July 2021.

  • Open Access

    Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis

    by On behalf of the Belgian Association for the Study of the Liver (BASL), Adrienne Lejeune, Peter Stärkel, Alexandre Louvet, Axel Hittelet, Céline Bazille, Boris Bastens, Hans Orlent, Luc Lasser, Xavier Dekoninck, et al.

    Background: Keratin 7 positive (K7+) cells are considered to be activated in case of impaired hepatocyte replication. Their exact role and their interaction with hepatocytes and macrophages also implicated in liver regeneration remain poorly characterized in humans. The aim of this study is to evaluate hepatocyte, K7+ cells and macrophage populations in severe alcohol-related steatohepatitis (sASH) and to link them with liver injury and patients’ outcomes. Methods: Immunohistochemical and morphometric studies for total K7+ cells, macrophages (CD68+ cells), proliferative hepatocytes (Ki67+ hepatocytes) and proliferative K7+ cells (double K7+ and Ki67+) were performed on liver biopsies of patients with sASH recruited prospectively in 16 different centres. Patients were divided into improvers or non-improvers, according to mortality and model for end-stage liver disease (MELD) score change at 3 months. Results: Fifty-seven cases were included for histological and morphometrical assessment. Liver total K7+ cell expansion was positively correlated to the severity of the disease evaluated by the MELD score. A proportion of these K7+ cells were proliferating. The number of proliferating K7+ cells was less than the number of proliferating hepatocytes. Increased hepatocyte replication was correlated to a higher proliferative K7+ cell count. A higher number of macrophages was associated with a higher proliferation of both hepatocytes and K7+ cells. No difference of total K7+ cells, proliferative K7+ cells, proliferative hepatocytes or macrophages was observed between improvers and non-improvers. Conclusions: In biopsy-proven cases of sASH, proliferation of hepatocytes and K7+ cells occurs in parallel. This could suggest that liver progenitor cells begin to replicate even in the absence of massive hepatocyte senescence in humans, or that proliferating progenitor cells are capable of giving rise to hepatocytes with replicative skills. This is associated with macrophagic expansion, which is therefore considered beneficial. However, in this severe, life-threatening disease, these mechanisms remain insufficient to improve patient prognosis.


  • Open Access

    Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study

    by Jean-Charles Nault, Nanthara Sritharan, Gontran Verset, Ivan Borbath, Marie Lequoy, Manon Allaire, Hélène Regnault, Isabelle Colle, Hans Orlent, Isabelle Sinapi, et al.


  • Open Access

    A multicentre interventional study to assess blood-borne viral infections in Belgian prisons

    by Dana Busschots, Cécile Kremer, Rob Bielen, Özgür M. Koc, Leen Heyens, Christian Brixko, Pierre Laukens, Hans Orlent, Pascal Bilaey, Francis De Smet, et al.

    Background: Prevalence data on viral hepatitis B (HBV), hepatitis C (HCV), and HIV infection in prison are often scarce or outdated. There is currently no systematic screening for these blood-borne viral infections (BBV) in Belgian prisons. There is an urgency to assess the prevalence of these BBV to inform policymakers and public healthcare. Methods: This was a multicentre, interventional study to assess the prevalence of BBV using opt-in screening in prisons across Belgium, April 2019 – March 2020. Prisoners were tested using a finger prick and BBV risk factors were assessed using a questionnaire. A generalized linear mixed model was used to investigate the association between the various risk factors and HCV. Results: In total, 886 prisoners from 11 Belgian prisons were screened. Study uptake ranged from 16.9 to 35.4% in long-term facilities. The prevalence of HCV antibodies (Ab), hepatitis B surface antigen (Ag) and HIV Ab/Ag was 5.0% (44/886), 0.8% (7/886), and 0.2% (2/886). The adjusted odds for HCV Ab were highest in prisoners who ever injected (p < 0.001; AOR 24.6 CI 95% (5.5–215.2). The prevalence of detectable HCV RNA in the total cohort was 2.1% (19/886). Thirteen (68.4%) prisoners were redirected for follow-up of their HCV infection. Conclusions: Opt-in testing for viral hepatitis B, C and HIV was relatively well-accepted in prisons. Compared with the general population, prisoners have a higher prevalence of infection with BBV, especially for HCV. Systematic screening for these BBV should be recommended in all prisons, preferably using opt-out to optimize screening uptake. Trial registration: Retrospectively registered at clinical trials NCT04366492 April 29, 2020.


  • Disseminated Mycobacterium genavense infection in an immunocompetent adult: a case report

    by G. Cornelis, M. Reynders, J. Deprez, A. Vankeerberghen, H. Orlent


  • Open Access

    Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

    by Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M. Schattenberg, Peter Buggisch, Sven Francque, et al.

    A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naïve and prior-relapse patients. The study comprised four 12-week treatment panels: Panel 1 (n = 10; GT1a) and Panel 2-Arm 1 (n = 12; GT1b): simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000–1200 mg/day; Panel 2-Arm 2 (n = 9; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1: n = 22; GT1a/GT1b) or 60 mg once daily (Arm 2: n = 22; GT1a/GT1b). Primary endpoint was sustained virologic response 12 weeks after end of treatment (12 weeks of combination treatment; SVR12). In Panel 1 and Panel 2-Arm 1, 5/10 and 6/12 (50%) GT1a/GT1b + ribavirin patients achieved SVR12, versus 3/9 (33%) GT1b without ribavirin patients in Panel 2-Arm 2. In Panel 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin and 4/8 (50%) GT1b without ribavirin patients, respectively, achieved SVR12. In Panel 4, 10/14 (71%) and 14/15 (93%) GT1a patients in Arms 1 and 2 achieved SVR12 compared with 8/8 and 7/7 (100%) GT1b patients in each arm, respectively. No deaths, serious adverse events (AEs), Grade 4 AEs or AEs leading to treatment discontinuation occurred. The 2- and 3-DAA combinations were well tolerated. High SVR rates of 93% and 100% in GT1a- and GT1b-infected patients, respectively, were achieved in this study by combining simeprevir with JNJ-56914845 60 mg and TMC647055/ritonavir. NCT01724086 (date of registration: September 26, 2012)


  • Open Access

    Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form

    by Wim Schuermans, Hans Orlent, Isabelle Desombere, Patrick Descheemaeker, Hans Van Vlierberghe, Anja Geerts, Xavier Verhelst, Marijke Reynders, Elizaveta Padalko

    As different hepatitis C virus (HCV) genotypes respond differently to initiated therapy, correct HCV genotyping is essential. A potential risk for misclassification of the intergenotypic HCV circulating recombinant form (CRF) 2k/1b strains exists, depending on the genotyping method used. The aim was to investigate the differences in HCV genotyping methods with regard to CRF 2k/1b and to gain insight in the prevalence of the CRF 2k/1b. Genotyping results by Versant HCV Genotype Assay were compared with nonstructural protein 5B (NS5B) sequencing. In total, from November 2001 until March 2015, 3296 serum samples were analyzed by Versant HCV Genotype Assay. As misclassified CRF is harbored among HCV genotype 2, we further focused our search on 142 (4.3%) samples positive for HCV genotype 2. On 116 (81.7%) retrieved samples, the NS5B sequencing was performed. Twelve out of the 116 retrieved samples (10.3%) were classified as CRF 2k/1b by sequencing of the NS5B region. Ten of these 12 samples were originally misclassified as genotype 2a or 2c, while 2 of them were misclassified as genotype 2. Our results show that the current prevalence of CRF 2k/1b is underestimated. The importance of correct HCV genotyping is emphasized, considering the tailored choice of treatment regimen and overall prognosis.


    • 1 June 2012
      • Vol. 75  (2) , 245-59

    Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

    by Hans Orlent, Pierre Deltenre, Sven Francque, Wim Laleman, Christophe Moreno, Stefan Bourgeois, Isabelle Colle, Jean Delwaide, Stéphane De Maeght, Jean-Pierre Mulkay, et al.


  • Open Access

    A case of emphysematous gastritis

    by X. Verhelst, M. Cabooter, V. de Wilde, P. Laukens, H. Orlent

    A 71-year-old man was referred with food intolerance leading to a weight loss of 12 kg. Three weeks earlier, he had presented at another hospital with severe upper abdominal pain and fever. He was treated with intravenous fluids and ciprofloxacin and recovered rapidly. CT imaging 3 weeks later showed mucosal edema of the stomach with air and fluid collections within the gastric wall ([ Fig. 1 ]). Esophagogastroduodenoscopy (Olympus GIF H180) showed significant edema of the gastric mucosa, creating a tunnel view leading to the pylorus. In the antrum, two ulcer-like lesions covered by pus were observed along the greater curvature. Intubation of these lesions with a small-caliber scope (Olympus GIFXP180N) showed loosening of the gastric mucosa, which had a puff-pastry appearance ([ Video 1 ]). This led us to a diagnosis of emphysematous gastritis. Gram staining of the aspirated pus showed the presence of gram-positive cocci and bacilli. A culture grew Candida albicans. Treatment with piperacillin–tazobactam, metronidazole, and fluconazole was started and the patient was fed by nasojejunal tube. He ultimately had a full recovery, gaining 20 kg in weight over the ensuing year. Eighteen months later the patient presented again with postprandial vomiting and acid regurgitations accompanied by a rapid weight loss of 10 kg. His C-reactive protein concentration was elevated. CT scan showed a thickening of the antral gastric wall with reappearance of air inclusions. A subtotal gastrectomy was performed. An impacted food granuloma was observed in the submucosal layers of the antrum, with surrounding inflammation and fibrosis. Emphysematous gastritis is a rare disease with a poor overall prognosis; it is caused by invasion of the gastric wall by gas-forming micro-organisms [1] [2]. Patients who do not respond to conservative treatment or have severe necrosis should be considered for surgery. The follow-up of our case shows that ultimately a subtotal gastrectomy may be indicated despite an initial complete recovery with the conservative approach. Endoscopy_UCTN_Code_CCL_1AB_2AD_3AF